Adial Pharmaceuticals files AD04 utility application with USPTO

Adial Pharmaceuticals (ADIL) announced the filing of a new U.S. utility application with the United States Patent and Trade Office, or USPTO, directed to AD04, the company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients. Once the patent is granted, it is expected to protect Adial’s core assets through at least 2045. The application is being filed with a request for track one prioritized examination to expedite examination. The advantages of a track one prioritized examination include a substantially shorter examination time that will assist Adial with early patentability insights to refine strategy and a condensed prosecution.